The combination of vibostolimab and pembrolizumab demonstrated promising antitumor activity and was well-tolerated in patients with advanced NSCLC who were naïve to anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.